Viking Therapeutics Faces Repricing as VK2735 Phase 3 Delayed to Q3 2026
PILLAR DIAGNOSTIC // WEEK 07
“A pervasive timeline error shows Phase 3 won’t start until Q3 2026 rather than this year, yet investors have priced in a near-term catalyst—look for shares to reprice lower once the delay is fully recognized.”
Proposed action
Avoid chasing near-term upside and consider trimming exposure until timeline clarity is provided.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
VKTX accelerated VK2735 into late‐stage development with Vanquish 1 enrollment completed ahead of schedule, plans to file an IND in Q1 2026, and maintains over $700 million in cash, while surging R&D spend drove a Q4 2025 net loss of $157.7 million ($1.38/share) and annual R&D expenses rose to $345 million.
THE MAP
Structure & constraints
—
THE MOOD
Consensus & positioning
Advancement of the oral obesity candidate to Phase 3 and strong cash runway have fueled investor optimism, while lingering concerns around clinical uncertainty, rising losses and valuation relative to peers temper sentiment.
